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Sir,
In his letter, Dr O’Mahony (2012) makes two main points. The
first of these relates to the number of alternatives explored during
our assessment of colorectal cancer screening in Ireland (Sharp
et al, 2012), and the second relates to the terminology used in the
paper.
Our paper reports findings from a health technology assessment
(HTA) of colorectal cancer screening; the full report has been
published (Health Information and Quality Authority, 2009a). The
purpose of HTA is to inform decision makers about the relative
efficacy and costs of possible health-care interventions in order
that coherent policy decisions can be taken. In the case of our
work, the question of interest was whether population screening
for colorectal cancer in Ireland would be effective and cost-
effective.
The initial phase of an HTA involves scoping the assessment.
During this process, the alternative screening strategies to be
considered were identified. The selection of the screening scenarios
that would be considered was informed by an Expert Group
established by the commissioners, the Health Information and
Quality Authority, to oversee the evaluation. In an ideal world, all
possible interventions (an exhaustive and mutually exclusive list of
alternative courses of action) would be considered. However, some
options may be excluded because they are deemed infeasible to
implement (e.g., due to insufficient endoscopy capacity) or
unacceptable to the service providers (e.g., due to risk of death
associated with the technology). It may also be impractical to detail
all alternatives (e.g., every possible screening frequency or
combination of tests). Specifically, in our HTA, whether to
consider screening by colonoscopy or CT colonography was
discussed at this stage; the former was considered to be associated
with unacceptably high risks of death and the latter was considered
as both unfeasible and to have an insufficient evidence base. Thus,
after scoping, the actual number of alternatives to be investigated
in the detailed modelling was fewer than the initial set examined.
The second point made in the letter is that of terminology. The
concept of ICERs and ACERs is discussed, and the received
interpretation of them is highlighted. In our HTA, the results are
provided in a disaggregated fashion (as is recommended by 5.7.6 of
the NICE methods guidance, 2008) (National Institute for Health
and Clinical Excellence, 2008). This allows a proper comparison to
be made between the interventions, and ensures that the decision
maker does not blindly adopt a course of action deemed to be
‘cost-effective’ by reference to the ICER alone. It also permits other
readers to calculate ICERs for many different comparisons should
they so wish. Similarly, it is possible to evaluate any scenario vs no
screening (which equates to an ACER, but also to the ICER when
other options become infeasible).
An additional consideration when carrying out an HTA is how
uncertainty in model inputs will be treated. Our analysis included a
full probabilistic sensitivity analysis (PSA). Doing this involves
greater consideration of the details of each scenario, but provides
better information for the decision maker. For similar strategies
(such as limiting screening to particular age groups), the relative
cost-effectiveness of each was indistinguishable in the PSA. That is,
the uncertainty made it impossible to determine which was the
most cost-effective. This provides another reason to include a
limited number of scenarios and to provide results in a
disaggregated manner.
Since our HTA was conducted, additional work has been carried
out by the Health Information and Quality Authority to establish
how a screening programme, although cost-effective, might be
funded at a national level (Health Information and Quality
Authority, 2009b). Following this work, a decision was made to
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implement a population-based colorectal cancer screening pro-
gramme in Ireland, based on biennial faecal immunochemical
testing. Significant progress has been made towards this objective
(National Cancer Screening Service, 2012). This process illustrates
very effectively how the reality of limited resources means that
HTA is of increasing importance for decision makers in
prioritising health-care interventions.
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